| SLE | Anti-dsDNA antibody | 50–75 | Disease activity, frequent in pediatric SLE |
| Anti-Ro/SSA antibody | 25–30 | Neonatal lupus, SCLE |
| Anti-La/SSB antibody | 10–30 | Neonatal lupus |
| Anti-Smith (Sm) antibody | 15–30 | Highly specific |
| Anti-U1-RNP antibody | 30–40 | Raynaud’s phenomenon |
| Anti-histone antibody | 50–70 | Drug-induced LE |
| Anti-ribosomal P antibody | 10–20 | Neuropsychiatric SLE |
| Systemic sclerosis (SSc) | Anti-Scl-70 antibody | 20–60 | Diffuse SSc, interstitial lung disease |
| Anti-centromere antibody | 30–35 | Limited SSc |
| Anti-RNA Pol III antibody | 4–25 | Diffuse SSc, renal crisis |
| Sjögren syndrome (SjS) | Anti-Ro/SSA antibody | 40–70 | SCLE, interstitial lung disease (52 kD) |
| Anti-La/SSB antibody | 30–60 | |
| Rheumatoid arthritis (RA) | Anti-histone antibody | 5–10 | |
| Anti-Ro/SSA antibody | 3–10 | Secondary Sjögren syndrome |
| MCTD | Anti-U1-RNP antibody | 100 | Essential criterion for diagnosis |
| IIM (e.g., DM/PM) | Anti-Jo-1 antibody | 20–30 | Diagnostic score, interstitial lung disease |